News

Who We Are
09.05.2011

InCROM Group and HMR collaborate over bridging studies

HMR and InCROM have agreed to work together to provide a full service for clinical trials across all phases of drug development, especially in Japanese people, by using their respective resources in the UK, Japan and China.

InCROM Group is a Japanese-owned SMO/CRO with bases in Japan and China. InCROM does phase 1, 2 and 3 clinical trials in Japan, and phase 3 and 4 clinical trials in China. InCROM was one of the first companies to provide a commercial service for clinical trials in Japan, and the first to establish a dedicated hospital for clinical trials in that country.

HMR is a CRO that does phase 1 and early phase 2 trials in the UK. One of its specialist services is 'bridging studies' in healthy Japanese people living in the UK.


Back to list
National Training Awards Cyber Essentials Digital XRaid A proud member of UK BioIndustry Association one nucleus
certificate